Abbott Laboratories
XHAM:ABL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Abbott Laboratories
XHAM:ABL
|
US |
|
Asics Corp
F:ASI
|
JP |
|
C
|
Constellation Brands Inc
XMUN:CB1A
|
US |
|
Sabra Health Care REIT Inc
F:SBC
|
US |
|
A
|
Agricultural Bank of China Ltd
XMUN:EK7
|
CN |
|
M
|
Medallion Financial Corp
F:MD5
|
US |
|
T
|
TJX Companies Inc
XMUN:TJX
|
US |
|
Verbund AG
F:OEWA
|
AT |
|
Agricultural Bank of China Ltd
F:EK7A
|
CN |
|
M
|
Marsh & McLennan Companies Inc
DUS:MSN
|
US |
Wall St Price Targets
ABL Price Targets Summary
Abbott Laboratories
According to Wall Street analysts, the average 1-year price target for ABL is 102.21 EUR with a low forecast of 77.82 EUR and a high forecast of 125.74 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ABL's stock price target?
Price Target
102.21
EUR
According to Wall Street analysts, the average 1-year price target for ABL is 102.21 EUR with a low forecast of 77.82 EUR and a high forecast of 125.74 EUR.
What is the Revenue forecast for Abbott Laboratories?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 7 years is 9%.
What is the Operating Income forecast for Abbott Laboratories?
Projected CAGR
14%
Over the last 13 years, the compound annual growth rate for Operating Income has been 15%. The projected CAGR for the next 7 years is 14%.
What is the Net Income forecast for Abbott Laboratories?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Net Income has been 1%. The projected CAGR for the next 7 years is 15%.
